A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-07. Anything still debated is marked as such rather than presented as settled.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
phosphorylation Aside from cleavage, phosphorylation is perhaps the most important chemical modification of proteins. A phosphate group can be attached to the sidechain hydroxyl group of serine, threonine and tyrosine residues, adding a negative charge at that site and producing an unnatural amino acid. Such reactions are catalyzed by kinases and the reverse reaction is catalyzed by phosphatases. The phosphorylated tyrosines are often used as "handles" by which proteins can bind to one another, whereas phosphorylation of Ser/Thr often induces conformational changes, presumably because of the introduced negative charge. The effects of phosphorylating Ser/Thr can sometimes be simulated by mutating the Ser/Thr residue to glutamate. glycosylation A catch-all name for a set of very common and very heterogeneous chemical modifications. Sugar moieties can be attached to the sidechain hydroxyl groups of Ser/Thr or to the sidechain amide groups of Asn. Such attachments can serve many functions, ranging from increasing solubility to complex recognition. All glycosylation can be blocked with certain inhibitors, such as tunicamycin. deamidation (succinimide formation) In this modification, an asparagine or aspartate side chain attacks the following peptide bond, forming a symmetrical succinimide intermediate. Hydrolysis of the intermediate produces either aspartate or the β-amino acid, iso(Asp). For asparagine, either product results in the loss of the amide group, hence "deamidation".
==== Nuts ==== A species of hard nut is gaining popularity as a replacement for ivory, although its size limits its usability. It is sometimes called vegetable ivory, or tagua, and is the seed endosperm of the ivory nut palm commonly found in coastal rainforests of Ecuador, Peru and Colombia.
In 1930 Cecil George Paine, a pathologist at the Royal Infirmary in Sheffield, successfully treated ophthalmia neonatorum, a gonococcal infection in infants, with penicillin (fungal extract) on 25 November 1930. In 1940 the Australian scientist Howard Florey (later Baron Florey) and a team of researchers (Ernst Chain, Edward Abraham, Arthur Duncan Gardner, Norman Heatley, Margaret Jennings, Jean Orr-Ewing and Arthur Gordon Sanders) at the Sir William Dunn School of Pathology of the University of Oxford made progress in making concentrated penicillin from fungal culture broth that showed both in vitro and in vivo bactericidal action. In 1941 they treated a policeman, Albert Alexander, with a severe face infection; his condition improved, but then supplies of penicillin ran out and he died. Subsequently, several other patients were treated successfully. In December 1942, survivors of the Cocoanut Grove fire in Boston, United States, were the first burn patients to be successfully treated with penicillin. The first successful use of pure penicillin was in 1942 when Fleming cured Harry Lambert of an infection of the nervous system (streptococcal meningitis) which would otherwise have been fatal. By that time the Oxford team could produce only a small amount. Florey willingly gave the only available sample to Fleming. Lambert showed improvement from the very next day of the treatment, and was completely cured within a week. Fleming published his clinical trial in The Lancet in 1943.
==== Doggie Kruger ==== Anubian Doggie Kruger (アヌビス星人ドギー・クルーガー, Anubisu Seijin Dogī Kurūgā), also known as "Boss" (ボス, Bosu) to several of his subordinates, is from Planet Anubis and is the tough-yet-honorable superintendent of the Space Police's Metropolitan Police, as well as chief of its Earth branch. While operating as a Dekaranger in his younger years, he earned a legendary reputation as "Hell's Guard Dog" (地獄の番犬, Jigoku no Banken), due in part to his willingness to do anything to save those he cares about. Despite this, he displays feelings for his assistant Swan and panics whenever he hears she has an admirer. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Kruger investigated the alleged corruption of his superior Kight Reidlich, and was framed for murder and held captive for two years before his team rescues him in the present. Soon after, Kruger admits his feelings for Swan. In battle, Kruger is a practitioner of the Galaxy Sword-Style (銀河一刀流, Ginga Ittō-ryū) where he learned the style's secret technique, the Vega Impulse (ベガインパルス, Bega Inparusu). Though he is capable of destroying 100 foes without being defeated, he suffered from a spinal problem that caused him to miss once every 2000 attacks until being cured by chiropractor Yukito Sanjyo of the Abarangers. Additionally, utilizing a variant of the SP License called the Master License (マスターライセンス, Masutā Raisensu), Kruger can transform into the black-colored Deka Master (デカマスター, Deka Masutā).
Sources: en.wikipedia.org
== Children == A child's exposure to contaminants in the air can have detrimental health effects including heightened risk of respiratory tract infections, increased likelihood of childhood asthma, behavioural problems and reduced neurocognitive abilities. Exposure to mainstream and sidestream smoke in childhood poses an increased risk of coughing, wheezing, and mucus production. Studies on rats have shown that those who were exposed to sidestream smoke while in utero and following the period directly after, had differences in airway sensitivity in comparison to those that had been exposed to sidestream smoke only while in utero or only following the period after.
Later, Justice Minister Aníbal Torres reassured the press that a question of confidence would not be used to defend Maraví. However, PM Bellido said that Torres' statement "is an opinion of the minister," and affirmed that using the question of confidence to defend Maraví wasn't ruled out. The press reported that Congress planned to wait until 7 October 2021, which was when a reinterpretation of the question of trust came into effect after having been approved on 17 September 2021. The reinterpretation would forbid the Prime Minister from raising the question of trust for constitutional reform bills and for issues that were the exclusive competence of the Congress of the Republic. According to sources consulted, the Congressional would claim that censuring ministers is a competence of the legislature in which the Government cannot intervene. Previously, Aníbal Torres criticized Congress' move to reinterpret the question of confidence, saying that it violated the balance of power established by the Constitution. Torres has stated that if Congress tries to promulgate the reinterpretation, then the Government will present an action of unconstitutionality. This case would be overseen by the Constitutional Court. It is worth noting that Congress has begun the election of new judges for the Constitutional Court. The mandate for the current Constitutional Court expired in 2019, but they kept serving as Congress couldn't agree on replacements. The Congressional opposition's attempt to impeach Iber Maraví was abruptly cut by the dissolution of the Bellido cabinet.
Rapid Communications in Mass Spectrometry (RCM) is a biweekly peer-reviewed scientific journal published since 1987 by John Wiley & Sons. It covers research on all aspects of mass spectrometry. According to the Journal Citation Reports, the journal has a 2020 impact factor of 2.419.
Sources: en.wikipedia.org
=== Automobiles === C4, a class of Audi 100 and Audi A6 cars Chevrolet Corvette (C4), the fourth production design of the Chevrolet Corvette Citroën C4, a car made by Citroën Coloni C4, a Formula One car built by Enzo Coloni Racing Car Systems Sauber C4, a Sauber sportscar Spyker C4, a Spyker car
Following Rollins' discovery in 1920 that lead aprons protected against X-rays, lead aprons with a lead thickness of 0.5 mm were introduced. Due to their weight, lead-free and lead-reduced aprons were subsequently developed. In 2005, it was recognized that in some cases the protection was significantly less than wearing lead aprons. The lead-free aprons contain tin, antimony and barium, which have the property of producing intense radiation (X-ray fluorescence radiation) when irradiated. In Germany, the Radiology Standards Committee has taken up the issue and introduced a German standard (DIN 6857-1) in 2009. The international standard IEC 61331-3:2014 was finally published in 2014. Protective aprons that do not comply with DIN 6857-1 of 2009 or the new IEC 61331-1 of 2014 may result in higher exposures. There are two classes of lead equivalency classes: 0.25 mm and 0.35 mm. The manufacturer must specify the area weight in kg/m2 at which the protective effect of a pure lead apron of 0.25 or 0.35 mm Pb is achieved. The protective effect of an apron shall be appropriate to the energy range used, up to 110 kV for low energy aprons and up to 150 kV for high energy aprons. If necessary, lead glass panels must also be used, with the front panels having a lead equivalent of 0.5-1.0 mm, depending on the application, and the side shields having a lead equivalent of 0.5-0.75 mm. Outside the useful beam, radiation exposure is primarily caused by scattered radiation from the tissue being scanned.
The conidia typically retain at least one adjacent spore-producing cell when broken away from the sporodochia, distinguishing A. roeperi conidiogenous structures from the less swollen, non-detachable conidiophores of A. xylebori; the original species description suggests this feature is meant to allow these units to snap off easily while X. crassiusculus is grazing upon the gallery. When within the beetle mycangium (a pocket in the insect cuticle for fungal dispersal), A. roeperi can be found as small, several-cell chains with crosswalls; this material is likely derived from chunks of mycelium scraped from the gallery walls and may thus constitute an arthrospore-like structure. Notably, this indicates that the conidia produced in the galleries are unlikely to act as the predominant dispersive forms of A. roeperi, and beetles instead transport fungi to new trees as disarticulated hyphae.
==== Serotonergic pathway regulation ==== KOR activation suppresses serotonergic signaling through multiple mechanisms, including regulation of the serotonin transporter (SERT) via intracellular kinase cascades. Dynorphin, released from local GABAergic neurons within reward-related regions, can bind to KORs expressed on serotonergic terminals projecting from the DRN to regions such as NAcc, prefrontal cortex, and other limbic structures associated with mood regulation. Agonist-induced binding to these receptors triggers rapid, concentration-dependent upregulation of SERT function through CaMKII and Akt. This increased trafficking of SERT to the plasma membrane, enhances serotonin reuptake via p38 MAPK-mediated recruitment, coupled with increased phosphorylation of the transporter protein, reducing serotonin's functional availability to the postsynaptic 5‑HT1A and other 5‑HT receptor subtypes. Beyond depleting serotonin levels, KOR agonism directly interferes with the signaling efficacy of 5-HT1A receptor G-protein through competition as both receptors are coupled to Gi/0. The presence of KOR agonists depletes the available pool of the heterotrimeric G-proteins and the receptor's mutant variant I135L which has a high basal activity inhibits signaling mediated by the 5-HT1A. In the NAcc, stress-dependent upregulation of postsynaptic 5-HT1B receptors co-expressed on direct pathway neurons expressing prodynorphin is an additional downstream mechanism.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.